Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors - PubMed

Review

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

Catherine Delbaldo et al. Target Oncol. 2011 Jun.

Abstract

In the quest for personalized medicine, only a few biological parameters are routinely used to select patients prior to the initiation of anticancer targeted therapies, including mTOR inhibitors. Identifying biological factors that may predict efficacy or resistance to mTOR inhibitors represents an important challenge since rapalogs may exert antitumor effects through multiple mechanisms of action. Despite the fact that no such a factor is currently available, several molecular patterns are emerging, correlating with sensitivity and/or resistance to rapalogs. While activation of the phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, overexpression of cyclin D1, and functional apoptosis seem to sensitize tumor cells to rapalogs, Bcl2 overexpression or KRAS mutations are reported to be associated with resistance to mTOR inhibitors in several preclinical models. Translational research aimed at validating those parameters in clinical trials is ongoing.

Similar articles

• Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

  Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Alvarado Y, et al. Target Oncol. 2011 Jun;6(2):69-94. doi: 10.1007/s11523-011-0178-5. Epub 2011 May 4. Target Oncol. 2011. PMID: 21541789 Review.

• Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.

  Gonzalez-Angulo AM, Blumenschein GR Jr. Gonzalez-Angulo AM, et al. Cancer Treat Rev. 2013 Jun;39(4):313-20. doi: 10.1016/j.ctrv.2012.11.002. Epub 2012 Dec 6. Cancer Treat Rev. 2013. PMID: 23218708 Free PMC article.

• Current treatment strategies for inhibiting mTOR in cancer.

  Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Chiarini F, et al. Trends Pharmacol Sci. 2015 Feb;36(2):124-35. doi: 10.1016/j.tips.2014.11.004. Epub 2014 Dec 11. Trends Pharmacol Sci. 2015. PMID: 25497227 Review.

• mTOR signaling pathway and mTOR inhibitors in cancer therapy.

  Gomez-Pinillos A, Ferrari AC. Gomez-Pinillos A, et al. Hematol Oncol Clin North Am. 2012 Jun;26(3):483-505, vii. doi: 10.1016/j.hoc.2012.02.014. Epub 2012 Mar 31. Hematol Oncol Clin North Am. 2012. PMID: 22520976 Review.

• Updates of mTOR inhibitors.

  Zhou H, Luo Y, Huang S. Zhou H, et al. Anticancer Agents Med Chem. 2010 Sep;10(7):571-81. doi: 10.2174/187152010793498663. Anticancer Agents Med Chem. 2010. PMID: 20812900 Free PMC article. Review.

Cited by

• Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.

  Watari K, Nishitani A, Shibata T, Noda M, Kawahara A, Akiba J, Murakami Y, Yano H, Kuwano M, Ono M. Watari K, et al. Oncotarget. 2016 Jul 26;7(30):47403-47417. doi: 10.18632/oncotarget.10161. Oncotarget. 2016. PMID: 27329724 Free PMC article.

• MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.

  Wang Y, Zhang M, Wang Z, Guo W, Yang D. Wang Y, et al. Mol Carcinog. 2020 Oct;59(10):1188-1198. doi: 10.1002/mc.23248. Epub 2020 Aug 18. Mol Carcinog. 2020. PMID: 32810332 Free PMC article.

• Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.

  Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyal F, Cosulich S, Diéras V, Bièche I, Marangoni E. Hatem R, et al. Oncotarget. 2016 Jul 26;7(30):48206-48219. doi: 10.18632/oncotarget.10195. Oncotarget. 2016. PMID: 27374081 Free PMC article.

• Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

  Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S. Tijeras-Raballand A, et al. Target Oncol. 2012 Sep;7(3):173-81. doi: 10.1007/s11523-012-0229-6. Epub 2012 Aug 25. Target Oncol. 2012. PMID: 22923165 Review.

• Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

  Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Alvarado Y, et al. Target Oncol. 2011 Jun;6(2):69-94. doi: 10.1007/s11523-011-0178-5. Epub 2011 May 4. Target Oncol. 2011. PMID: 21541789 Review.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal